Genentech Oncology
Breast cancer biomarkers (eg, hormone receptors, HER2) are used to identify patients who may benefit from targeted therapy3
HER2 status has been added to staging in a new clinical prognostic stage grouping to add additional information beyond the anatomic classification.7
Using 8th edition criteria, more than 35% of patients with HER2-positive tumors were reassigned to a stage group higher or lower than would otherwise be assigned using the 7th edition.7
ASCO/CAP=American Society of Clinical Oncology/College of American Pathologists; AJCC=American Joint Committee on Cancer; ER=estrogen receptor; HER2=human epidermal growth factor receptor 2; M=metastatic status; N=lymph node involvement; PgR=progesterone receptor; T=primary tumor
TNBCs:
PD-L1 may be expressed on both tumor cells and tumor-infiltrating immune cells13,15
Triple-negative breast cancer (TNBC) tumors are highly immunogenic, with high levels of tumor-infiltrating immune cells, and express programmed death-ligand 1 (PD-L1)16,17
Binding of the ligand PD-L1 to its inhibitory receptors programmed cell death-1 and B7.1 on T cells can suppress cytotoxic T-cell activity through T-cell deactivation13
When using the SP142 assay, IC staining for PD-L1 is prevalent across different tumor types19,20
For certain tumor types, such as TNBC, PD-L1 expression in immune cells is higher than in tumor cells, emphasizing the importance of scoring PD-L1 expression in immune cells.11
FFPE=formalin-fixed paraffin-embedded; NSCLC=non-small cell lung carcinoma; PD-L1=programmed death-ligand 1; TC=tumor cells.
American Cancer Society (ACS). Cancer Facts & Figures 2018. Atlanta, GA: American Cancer Society Inc.; 2018.
American Cancer Society (ACS). Cancer Facts & Figures 2018. Atlanta, GA: American Cancer Society Inc.; 2018.
American Cancer Society (ACS). Breast Cancer Facts 2017-2018. Atlanta, GA: American Cancer Society, Inc.; 2017.
American Cancer Society (ACS). Breast Cancer Facts 2017-2018. Atlanta, GA: American Cancer Society, Inc.; 2017.
Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V.4.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed October 31, 2022. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V.4.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed October 31, 2022. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
Wolff AC, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline update. J Clin Oncol. 2013;31:3997-4013. PMID: 24101045
Wolff AC, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline update. J Clin Oncol. 2013;31:3997-4013. PMID: 24101045
Howlander N, et al. US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status. J Natl Cancer Inst. 2014;106(5). PMID: 24777111
Howlander N, et al. US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status. J Natl Cancer Inst. 2014;106(5). PMID: 24777111
Wolff AC, et al. Human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2018. doi:10.5858/arpa.2018-0902-SA. PMID: 29846104
Wolff AC, et al. Human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2018. doi:10.5858/arpa.2018-0902-SA. PMID: 29846104
American Joint Committee on Cancer. AJCC Cancer Staging Manual. 8th ed. New York, NY: Springer; 2017.
American Joint Committee on Cancer. AJCC Cancer Staging Manual. 8th ed. New York, NY: Springer; 2017.
American Joint Committee on Cancer. AJCC Cancer Staging Poster. 7th ed. New York, NY: Springer; 2009.
American Joint Committee on Cancer. AJCC Cancer Staging Poster. 7th ed. New York, NY: Springer; 2009.
Székely B, et al. New therapeutic strategies for triple-negative breast cancer. Oncology (Williston Park). 2017;31:131-137. PMID: 28205193
Székely B, et al. New therapeutic strategies for triple-negative breast cancer. Oncology (Williston Park). 2017;31:131-137. PMID: 28205193
Foulkes WD, et al. Triple-negative breast cancer. N Engl J Med. 2010;363:1938-1948. PMID: 21067385
Foulkes WD, et al. Triple-negative breast cancer. N Engl J Med. 2010;363:1938-1948. PMID: 21067385
Li M, Li A, Zhou S, et al. Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer. BMC Cancer. 2018;18(1):4. doi: 10.1186/s12885-017-3916-y. PMID: 29291717
Li M, Li A, Zhou S, et al. Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer. BMC Cancer. 2018;18(1):4. doi: 10.1186/s12885-017-3916-y. PMID: 29291717
Lin NU, et al. Clinicopathological features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer. 2012;118:5463. PMID: 22544643
Lin NU, et al. Clinicopathological features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer. 2012;118:5463. PMID: 22544643
Chen DS, et al. Elements of cancer immunity and the cancer–immune set point. Nature. 2017;541:321-330. PMID: 28102259
Chen DS, et al. Elements of cancer immunity and the cancer–immune set point. Nature. 2017;541:321-330. PMID: 28102259
Hedge PS, et al. The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition. Clin Cancer Res. 2016;22:1865-1874. PMID: 27084740
Hedge PS, et al. The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition. Clin Cancer Res. 2016;22:1865-1874. PMID: 27084740
Mittendorf EA, et al. PD-L1 Expression in Triple-Negative Breast Cancer. Cancer Immunol Res. 2014;2(4):361-370. PMID: 24764583
Mittendorf EA, et al. PD-L1 Expression in Triple-Negative Breast Cancer. Cancer Immunol Res. 2014;2(4):361-370. PMID: 24764583
Liu Z, et al. A comprehensive immunologic portrait of triple-negative breast cancer. Transl Oncol. 2018;11:311. PMID: 29413765
Liu Z, et al. A comprehensive immunologic portrait of triple-negative breast cancer. Transl Oncol. 2018;11:311. PMID: 29413765
Gatalica Z, et al. Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. Cancer Epidemiol Biomarkers Prev. 2014;23:2965. PMID: 25392179
Gatalica Z, et al. Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. Cancer Epidemiol Biomarkers Prev. 2014;23:2965. PMID: 25392179
Schmid P, et al. N Engl J Med. 2018;379:2108. PMID: 30345906
Schmid P, et al. N Engl J Med. 2018;379:2108. PMID: 30345906
Emens LA, et al. Presented at: San Antonio Breast Cancer Symposium; December 4-8, 2018; San Antonio, TX.
Emens LA, et al. Presented at: San Antonio Breast Cancer Symposium; December 4-8, 2018; San Antonio, TX.
Rosenberg JE, et al. Lancet. 2016;387:1909-1920. PMID: 26952546
Rosenberg JE, et al. Lancet. 2016;387:1909-1920. PMID: 26952546
Genentech. Data on File. 2019.
Genentech. Data on File. 2019.
Fehrenbacher L, et al. Lancet. 2016;387:1837-1846. PMID: 26970723
Fehrenbacher L, et al. Lancet. 2016;387:1837-1846. PMID: 26970723
US Food and Drug Administration. Accessed November 22, 2022. https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools
US Food and Drug Administration. Accessed November 22, 2022. https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools
Roche. VENTANA PD-L1 (SP142) Assay Interpretation Guide for Triple-Negative Breast Carcinoma. 2019.
Roche. VENTANA PD-L1 (SP142) Assay Interpretation Guide for Triple-Negative Breast Carcinoma. 2019.
Learn more about the importance of oncologic biomarkers and what they can tell you.
Learn more about how cancer avoids immune response.
The compounds and their uses mentioned on this website are investigational and have not been approved by the US Food and Drug Administration. Efficacy and safety have not been established. The information presented should not be construed as a recommendation for use. Do you wish to proceed?
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.